Recognition of an Impairment Loss on Investment Securities (Extraordinary Loss) and Revision of the Full-Year Earnings Forecast
Japan Tissue Engineering Co.,Ltd. (reporting company)
Investment securities held by the company. Security name and issuer: Not disclosed
The securities were conservatively valued based on a comprehensive assessment of the issuers’ recent financial condition and other factors.
¥149 million (impairment loss on investment securities, extraordinary loss). The net income forecast is ¥194 million lower than the previous forecast.
Full fiscal year ending March 2026 (1 April 2025 to 31 March 2026)
The full-year earnings forecast has been revised. The revised forecast is revenue of ¥2,182 million, an operating loss of ¥549 million, an ordinary loss of ¥537 million, a net loss of ¥734 million, and a net loss per share of ¥18.09.
The company is currently preparing its financial statements and undergoing an accounting audit, and actual results may differ from the forecast figures. Revenue from the lab site business is expected to be deferred to the following fiscal year or later.
| Item | Details |
|---|---|
| Event name | Recognition of an Impairment Loss on Investment Securities (Extraordinary Loss) and Revision of the Full-Year Earnings Forecast |
| Subject Entity | Japan Tissue Engineering Co.,Ltd. (reporting company) |
| Target Locations / Products | Investment securities held by the company. Security name and issuer: Not disclosed |
| Cause | The securities were conservatively valued based on a comprehensive assessment of the issuers’ recent financial condition and other factors. |
| Amount of Impact on Business Performance | ¥149 million (impairment loss on investment securities, extraordinary loss). The net income forecast is ¥194 million lower than the previous forecast. |
| Accounting period in which recognized | Full fiscal year ending March 2026 (1 April 2025 to 31 March 2026) |
| Impact on Earnings Forecast | The full-year earnings forecast has been revised. The revised forecast is revenue of ¥2,182 million, an operating loss of ¥549 million, an ordinary loss of ¥537 million, a net loss of ¥734 million, and a net loss per share of ¥18.09. |
| Outlook | The company is currently preparing its financial statements and undergoing an accounting audit, and actual results may differ from the forecast figures. Revenue from the lab site business is expected to be deferred to the following fiscal year or later. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The impairment loss on investment securities was recognized after conservatively valuing the securities based on a comprehensive assessment of the issuers’ recent financial condition and other factors. The downward revision to revenue is primarily due to revenue from the lab site business being deferred to the following fiscal year or later. Operating profit and ordinary profit are expected to be broadly in line with the previously announced forecasts as a result of expense reductions. The downward revision to net income is due to the recognition of the ¥149 million impairment loss on investment securities and other items as extraordinary losses.